The KCTD9 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the human SK-HEP-1 liver adenocarcinoma cell line. These cells carry CRISPR/Cas9-mediated gene disruption of KCTD9, generating a loss-of-function model for functional studies. As a polyclonal knockout population, they consist of a heterogeneous mixture of cells harboring diverse editing alleles, which enables robust pooled genetic screens and avoids potential clonal artifacts associated with single?cell?derived clones.
SK-HEP-1 is an adherent epithelial cell line originally isolated from ascites of a patient with liver adenocarcinoma. It is a well?characterized model for hepatocellular carcinoma (HCC), widely employed to investigate liver cancer biology, tumor cell signaling, and therapeutic responses. This line retains key features of HCC, including altered proliferative and apoptotic regulation, making it a physiologically relevant host for studying oncogenic pathways and tumor?suppressor mechanisms.
KCTD9 encodes a substrate adaptor for Cullin?RING E3 ubiquitin ligase complexes, specifically interacting with Cullin proteins CUL3 and CUL4 to drive ubiquitination and proteasomal degradation of ???catenin (CTNNB1). By promoting ???catenin turnover, KCTD9 negatively regulates the Wnt/???catenin signaling pathway and suppresses the expression of TCF/LEF?responsive genes, including cyclin D1 and c?Myc. This places KCTD9 downstream of the canonical Wnt receptor complex (Frizzled/Dishevelled) and the ???catenin destruction complex (AXIN, APC, GSK3??), acting as an additional regulatory layer that reinforces signal silencing in the absence of Wnt ligands.
In hepatocellular carcinoma, KCTD9 functions as a tumor suppressor; its inactivation results in ???catenin accumulation, constitutive Wnt pathway activation, and enhanced malignant phenotypes such as unrestrained proliferation and apoptosis resistance. The KCTD9 Knockout SK?HEP?1 Polyclonal Cells thus provide a powerful tool to model the consequences of KCTD9 loss in liver cancer, facilitating dissection of the interplay between the ubiquitin?proteasome system and oncogenic Wnt signaling. This system is particularly valuable for examining how the transition from normal to pathological Wnt activity contributes to HCC progression.
These polyclonal knockout cells support a broad range of assays, including Western blot for KCTD9/???catenin/cyclin D1; RT?qPCR of Wnt target genes; TOP/FOP luciferase reporter assays; proliferation (MTS/CCK?8); apoptosis (Annexin V/PI); co?IP for KCTD9?C???catenin interaction; ubiquitination assays; and xenograft tumor growth. They are also a valuable platform for drug target validation of Wnt pathway inhibitors and for studying Cullin?RING E3 ligase mechanisms in HCC. For further technical information or to discuss custom applications, please contact Ascent Research.
